dc.contributor.author | Guijarro, Luis G. | |
dc.contributor.author | Chaparro Sánchez, María | |
dc.contributor.author | Vera Mendoza, María Isabel | |
dc.contributor.author | Martín Arranz, María Dolores | |
dc.contributor.author | Pérez Gisbert, Francisco Javier | |
dc.contributor.other | UAM. Departamento de Medicina | es_ES |
dc.date.accessioned | 2023-03-17T16:04:57Z | |
dc.date.available | 2023-03-17T16:04:57Z | |
dc.date.issued | 2022-03-21 | |
dc.identifier.citation | Biomedicines 10.3 (2022): 727 | en_US |
dc.identifier.issn | 2227-9059 (online) | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/706686 | |
dc.description.abstract | Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD). Methods: This study included 33 patients with CD (14 men and 19 women) who participated in the PREDICROHN project, a prospective multicenter study of the Spanish Group of Inflammatory bowel disease (GETECCU). Results: This article demonstrates declines with respect to baseline levels of serum AIF-1 in Crohn’s disease (CD) patients after 14 weeks of treatment with anti-TNFs. Furthermore, in patients with active CD (HB ≥ 5), serum AIF-1 levels were significantly higher than those in patients without activity (HB ≤ 4). The study of serum AIF-1 in the same cohort, revealed an area under the ROC curve (AUC) value of AUC = 0.66 (p = 0.014), while for the CRP (C-reactive protein), (AUC) value of 0.69 (p = 0.0066), indicating a similar ability to classify CD patients by their severity. However, the combination of data on serum levels of AIF-1 and CRP improves the predictive ability of these analyses for classifying CD patients as active (HB ≥ 5) or inactive (HB ≤ 4). When we used the odds ratio (OR) formula, we observed that patients with CRP > 5 mg/L or AIF-1 > 200 pg/mL or both conditions were 13 times more likely to show HB ≥ 5 (active CD) than were those with both markers below these thresholds. The development of an algorithm that includes serum levels of AIF-1 and CRP could be useful for assessing Crohn’s disease severity | en_US |
dc.description.sponsorship | This research has been funded by grants from: Asociación Española de Gastroenterología (AEG), Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU), Instituto de Salud Carlos III (FIS12/02557 and PI13/00041) and Universidad de Alcalá (32/2013, 22/2014, 26/2015) and B2017/BMD-3804 MITIC-CM (Comunidad de Madrid) and Halekulani S.L | en_US |
dc.format.extent | 14 pag. | es_ES |
dc.format.mimetype | application/pdf | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.relation.ispartof | Biomedicines | en_US |
dc.rights | © 2022 by the authors | en_US |
dc.subject.other | AIF-1 | en_US |
dc.subject.other | Anti-TNFs | en_US |
dc.subject.other | Crohn’s disease | en_US |
dc.subject.other | CRP | en_US |
dc.title | Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a biomarker of Crohn’s disease severity | en_US |
dc.type | article | en_US |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/biomedicines10030727 | en_US |
dc.identifier.doi | 10.3390/biomedicines10030727 | en_US |
dc.identifier.publicationfirstpage | 727-1 | es_ES |
dc.identifier.publicationissue | 3 | es_ES |
dc.identifier.publicationlastpage | 727_14 | es_ES |
dc.identifier.publicationvolume | 10 | es_ES |
dc.relation.projectID | Gobierno de España. FIS12/02557 | es_ES |
dc.relation.projectID | Gobierno de España. PIE-13-00041 | |
dc.relation.projectID | Comunidad de Madrid. B2017/BMD-3804 MITIC-CM | |
dc.type.version | info:eu-repo/semantics/publishedVersion | en_US |
dc.rights.cc | Reconocimiento | es_ES |
dc.rights.accessRights | openAccess | en_US |
dc.facultadUAM | Facultad de Medicina | es_ES |